Fundamental Analysis of EVOKE PHARMA INC(NASDAQ:EVOK) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to EVOK. EVOK was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of EVOK have multiple concerns. EVOK shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year EVOK has reported negative net income.

In the past year EVOK has reported a negative cash flow from operations.

EVOK had negative earnings in each of the past 5 years.

EVOK had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -110.17%, EVOK is doing worse than 84.62% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-110.17%
ROE	N/A
ROIC	N/A

ROA(3y)-86.8%

ROA(5y)-102.25%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

EVOK has a Gross Margin of 96.15%. This is amongst the best in the industry. EVOK outperforms 97.44% of its industry peers.

The Profit Margin and Operating Margin are not available for EVOK so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	96.15%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EVOK has about the same amout of shares outstanding than it did 1 year ago.

Compared to 5 years ago, EVOK has more shares outstanding

EVOK has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -26.28, we must say that EVOK is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -26.28, EVOK is not doing good in the industry: 89.23% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-26.28

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

EVOK has a Current Ratio of 2.25. This indicates that EVOK is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of EVOK (2.25) is worse than 62.05% of its industry peers.

EVOK has a Quick Ratio of 2.09. This indicates that EVOK is financially healthy and has no problem in meeting its short term obligations.

EVOK's Quick ratio of 2.09 is in line compared to the rest of the industry. EVOK outperforms 40.51% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.25
Quick Ratio	2.09

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

EVOK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.06%, which is quite good.

The Revenue has grown by 106.21% in the past year. This is a very strong growth!

EVOK shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 537.46% yearly.

EPS 1Y (TTM)13.06%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-11.32%

Revenue 1Y (TTM)106.21%

Revenue growth 3Y537.46%

Revenue growth 5YN/A

Revenue growth Q2Q109.5%

3.2 Future

The Earnings Per Share is expected to grow by 27.89% on average over the next years. This is a very strong growth

EVOK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 84.05% yearly.

EPS Next Y89.93%

EPS Next 2Y41.88%

EPS Next 3Y27.89%

EPS Next 5YN/A

Revenue Next Year174.1%

Revenue Next 2Y106.49%

Revenue Next 3Y84.05%

Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EVOK. In the last year negative earnings were reported.

Also next year EVOK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

EVOK's earnings are expected to grow with 27.89% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.88%

EPS Next 3Y27.89%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for EVOK!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EVOKE PHARMA INC

NASDAQ:EVOK (5/3/2024, 7:00:01 PM)

0.4855

+0.03 (+6.07%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap4.12M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-110.17%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	96.15%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.73

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.25
Quick Ratio	2.09
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)13.06%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y89.93%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)106.21%

Revenue growth 3Y537.46%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

EVOKE PHARMA INC (EVOK)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens